.
Obamacare did not solve that problem. It actually got even worse as shown by the increasing slope of that curve.
I know that and it's something that needs to be fixed.
The second part isn't as clear, you can't look at the slop of a linear chart of an exponential function to determine if the underlying rate of change is higher or lower.
One thing you can tell, though, his that either before or after Obamacare, the price of established drugs really shouldn't increase any faster than the rate of inflation.
Actually, Daraprim is an isolated case.
No, it's not. It's just the most extreme example. Here's more info:
Over the last year,
the committee investigated four drug companies, which it said had
all used a similar business model that included egregious price hikes to maximize profits.
The committee said that
Valeant offered a program that covered the cost of co-pays for privately-insured patients because executives knew it would reduce patients’ “incentive to complain to the press about Valeant’s outrageous price increases.”
By increasing prices rapidly, but covering patients’ co-pays, the companies could still make big profits, the committee said.
They used the example of
a drug priced at $100,000 that cost $10,000 to manufacture and distribute, leaving a potential profit of $90,000. If the company covered the patient’s $20,000 co-pay, the insurance company still paid $80,000 for the drug, resulting in a $70,000 profit for the company.
The patient assistance programs were a key method that Valeant used in raising the price of Cuprimine, used since 1956, and Syprine, developed in 1969, the committee said. Both drugs are used to treat Wilson disease, a rare condition in which the body cannot process copper.
Valeant raised the prices of Cuprimine and Syprine from about $500 to about $24,000 for a 30-day supply, the report said.
“The committee believes that these programs were driven not by altruism, but by Valeant’s desire to extract monopoly profits and then conceal that fact from the public,” the report said.
“In your thinking about this free market system you are describing,
is it a factor … [that] … t
he absence of Syprine could lead to liver failure or a liver transplant or even death? Is that a factor?” asked Sen.
Tim Kaine, a Virginia Democrat.
“It is,” Pearson responded.
The senators said they had evidence that other companies had used the same strategy to aggressively raise prices.
http://www.latimes.com/business/la-fi-senate-drug-price-study-20161221-story.html
More examples, the cost of the EpiPen follows a trajectory similar to insulin, jumping from under $100 to over $600 in a decade.
And
A House of Representatives report found in 2014 that
10 generic drugs experienced price increases just a year prior, ranging from a 420% hike to more than 8,000%.
Overall, prescription drug prices rise much faster than the rate of inflation.
And it's a US specific problem. One that existed before Obamacare and continues after Obamacare